{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T17:07:20Z","timestamp":1779037640901,"version":"3.51.4"},"reference-count":48,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"unspecified","delay-in-days":134,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"AstraZeneca K.K."}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2026,4,18]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate the real-world incidence of serious infections (SI), herpes zoster (HZ) and hepatitis B virus (HBV) reactivation among patients with SLE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective, non-interventional cohort study used an insurance claims database in Japan to calculate the incidence of SI requiring hospitalisation, HZ and HBV reactivation in patients with SLE from 1 April 2017 to 31 March 2021. As an exploratory analysis, HRs and 95% CIs were estimated for clinically relevant patient characteristics for SI and HZ, adjusting for age and sex.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 10 865 patients with SLE (female: 83.1%, median age: 53.0 years), including those who had previously experienced each complication, the incidence rates (per 100 patient-years) for SI, HZ and HBV reactivation were 4.80 (95% CI 4.53 to 5.08), 0.52 (0.44 to 0.61) and 0.37 (0.30 to 0.45), respectively. For those who had no previous history of each complication, incidence rates were 3.67 (3.44 to 3.92), 0.48 (0.40 to 0.58) and 0.25 (0.20 to 0.32), respectively. Incidence rates in specific subgroups were as follows: history of each complication (SI: 37.93, HZ: 4.19, HBV reactivation: 72.01), history of SI (HZ: 1.51, HBV reactivation: 1.75) and glucocorticoid pulse therapy during follow-up (SI: 64.23, HZ: 3.10, HBV reactivation: 4.85).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results provide data on the occurrence of selected infections in SLE and may inform safety management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/lupus-2025-001879","type":"journal-article","created":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T17:00:26Z","timestamp":1779037226000},"page":"e001879","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Incidence of serious infections, herpes zoster and hepatitis B virus reactivation among patients with SLE: a cohort study using a health claims database in Japan"],"prefix":"10.1136","volume":"13","author":[{"given":"Masataka","family":"Kuwana","sequence":"first","affiliation":[{"name":"Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Bunkyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6208-0590","authenticated-orcid":false,"given":"Toshiki","family":"Yabe-Wada","sequence":"additional","affiliation":[{"name":"Immunology, Respiratory & Immunology, Medical Department, AstraZeneca K.K., Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiro","family":"Hirai","sequence":"additional","affiliation":[{"name":"Data Science, Evidence & Observational Research, Medical Department, AstraZeneca K.K., Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Kato","sequence":"additional","affiliation":[{"name":"Medical Evidence Biopharma, Evidence & Observational Research, Medical Department, AstraZeneca K.K., Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7941-8396","authenticated-orcid":false,"given":"Yoshiyuki","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Immunology, Respiratory & Immunology, Medical Department, AstraZeneca K.K., Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,5,17]]},"reference":[{"key":"2026051710001996000_13.1.e001879.1","doi-asserted-by":"crossref","first-page":"v29","DOI":"10.1093\/rheumatology\/keaa382","article-title":"Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors","volume":"59","author":"Arnaud","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2026051710001996000_13.1.e001879.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2016.137"},{"key":"2026051710001996000_13.1.e001879.3","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key335"},{"key":"2026051710001996000_13.1.e001879.4","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224762"},{"key":"2026051710001996000_13.1.e001879.5","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)00398-2"},{"key":"2026051710001996000_13.1.e001879.6","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2022-000725","article-title":"Major infections in newly diagnosed systemic lupus erythematosus: an inception cohort study","volume":"9","author":"Wang","year":"2022","journal-title":"Lupus Sci Med"},{"key":"2026051710001996000_13.1.e001879.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2013.07.002"},{"key":"2026051710001996000_13.1.e001879.8","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/acr.22173","article-title":"Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies","volume":"66","author":"Yurkovich","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026051710001996000_13.1.e001879.9","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22179116","article-title":"High Risk of Viral Reactivation in Hepatitis B Patients with Systemic Lupus Erythematosus","volume":"22","author":"Chen","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026051710001996000_13.1.e001879.10","first-page":"189","article-title":"Lupus erythematosus and herpes zoster","volume":"19","author":"Hamaguchi","year":"1970","journal-title":"Mie Med J"},{"key":"2026051710001996000_13.1.e001879.11","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.1999.00490.x"},{"key":"2026051710001996000_13.1.e001879.12","doi-asserted-by":"publisher","DOI":"10.1136\/ard.49.8.630"},{"key":"2026051710001996000_13.1.e001879.13","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/1346-8138.15214","article-title":"Risk of herpes zoster in the Japanese population with immunocompromising and chronic disease conditions: Results from a claims database cohort study, from 2005 to 2014","volume":"47","author":"Imafuku","year":"2020","journal-title":"J Dermatol"},{"key":"2026051710001996000_13.1.e001879.14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1620\/tjem.237.9","article-title":"Pretreatment Screening for Hepatitis B Virus Infection in Patients with Systemic Lupus Erythematosus","volume":"237","author":"Watanabe","year":"2015","journal-title":"Tohoku J Exp Med"},{"key":"2026051710001996000_13.1.e001879.15","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/art.39849","article-title":"Comparative Rates of Serious Infections Among Patients With Systemic Lupus Erythematosus Receiving Immunosuppressive Medications","volume":"69","author":"Feldman","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2026051710001996000_13.1.e001879.16","first-page":"66","article-title":"Increased risk of hepatitis B virus reactivation in systemic lupus erythematosus patients receiving immunosuppressants: a retrospective cohort study","volume":"27","author":"Lin","year":"2018","journal-title":"Lupus (Los Angel)"},{"key":"2026051710001996000_13.1.e001879.17","unstructured":"Medical and healthcare database utilization committee, Japanese Society for Pharmacoepidemiology . Survey of Japanese databases in Japan available for clinical\/pharmacoepidemiology. Available: https:\/\/www.jspe.jp\/committee\/kenkou-iryou\/ [Accessed 30 Jun 2025]."},{"key":"2026051710001996000_13.1.e001879.18","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2013.778270"},{"key":"2026051710001996000_13.1.e001879.19","unstructured":"Sammaritano LR , Askanase A , Bermas BL , et al . 2025 American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus. Arthritis Care Res 2026."},{"key":"2026051710001996000_13.1.e001879.20","unstructured":"Japan Intractable Diseases Information Center . Number of people receiving benefits for designated intractable diseases. Available: https:\/\/www.nanbyou.or.jp\/entry\/5354 [Accessed 12 Jun 2025]."},{"key":"2026051710001996000_13.1.e001879.21","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1080\/13696998.2020.1740236","article-title":"Treatment patterns and medical cost of systemic lupus erythematosus patients in Japan: a retrospective claims database study","volume":"23","author":"Miyazaki","year":"2020","journal-title":"J Med Econ"},{"key":"2026051710001996000_13.1.e001879.22","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223035"},{"key":"2026051710001996000_13.1.e001879.23","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/mr\/roaf020","article-title":"Prevalence of systemic lupus erythematosus and age-stratified treatment trends in the Japanese population: A cross-sectional study based on the National Database of Health Insurance Claims","volume":"35","author":"Matsushita","year":"2025","journal-title":"Mod Rheumatol"},{"key":"2026051710001996000_13.1.e001879.24","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1093\/mr\/roae072","article-title":"Delayed global standardization and prefectural disparities in systemic lupus erythematosus treatment in Japan: A nationwide study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan","volume":"35","author":"Yokogawa","year":"2025","journal-title":"Mod Rheumatol"},{"key":"2026051710001996000_13.1.e001879.25","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-011-0434-0"},{"key":"2026051710001996000_13.1.e001879.26","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1111\/1756-185X.13363","article-title":"Disease severity and economic burden in Japanese patients with systemic lupus erythematosus: A retrospective, observational study","volume":"21","author":"Tanaka","year":"2018","journal-title":"Int J of Rheum Dis"},{"key":"2026051710001996000_13.1.e001879.27","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s40744-022-00525-x","article-title":"Serious Infection Rates Among Patients with Select Autoimmune Conditions: A Claims-Based Retrospective Cohort Study from Taiwan and the USA","volume":"10","author":"Huang","year":"2023","journal-title":"Rheumatol Ther"},{"key":"2026051710001996000_13.1.e001879.28","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1007\/s10067-023-06592-x","article-title":"Tuberculosis remains a leading contributor to morbidity due to serious infections in Indian patients of SLE","volume":"42","author":"Chatterjee","year":"2023","journal-title":"Clin Rheumatol"},{"key":"2026051710001996000_13.1.e001879.29","first-page":"1712","article-title":"The risk of hospitalized infection in patients with systemic lupus erythematosus treated with hydroxychloroquine","volume":"29","author":"Sakai","year":"2020","journal-title":"Lupus (Los Angel)"},{"key":"2026051710001996000_13.1.e001879.30","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150671"},{"key":"2026051710001996000_13.1.e001879.31","first-page":"704","article-title":"Risk factors for serious infections in inpatients with systemic lupus erythematosus","volume":"46","author":"Wang","year":"2021","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"key":"2026051710001996000_13.1.e001879.32","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13075-022-02869-9","article-title":"Association of low-dose glucocorticoid use and infection occurrence in systemic lupus erythematosus patients: a prospective cohort study","volume":"24","author":"Abe","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"2026051710001996000_13.1.e001879.33","doi-asserted-by":"crossref","first-page":"9704","DOI":"10.1038\/s41598-019-46039-5","article-title":"Associated clinical factors for serious infections in patients with systemic lupus erythematosus","volume":"9","author":"Jung","year":"2019","journal-title":"Sci Rep"},{"key":"2026051710001996000_13.1.e001879.34","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens13110934","article-title":"Infection-associated flares in systemic lupus erythematosus","volume":"13","author":"Ramirez","year":"2024","journal-title":"Pathogens"},{"key":"2026051710001996000_13.1.e001879.35","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-011-0162-0"},{"key":"2026051710001996000_13.1.e001879.36","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e3181d52ed7"},{"key":"2026051710001996000_13.1.e001879.37","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-020528","article-title":"Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000-2012","volume":"8","author":"Yanni","year":"2018","journal-title":"BMJ Open"},{"key":"2026051710001996000_13.1.e001879.38","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1590\/S1807-59322011000700009","article-title":"Risk of herpes zoster in patients with systemic lupus erythematosus: a three-year follow-up study using a nationwide population-based cohort","volume":"66","author":"Chen","year":"2011","journal-title":"Clinics (Sao Paulo)"},{"key":"2026051710001996000_13.1.e001879.39","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa636"},{"key":"2026051710001996000_13.1.e001879.40","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/art.39670","article-title":"Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination","volume":"68","author":"Yun","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2026051710001996000_13.1.e001879.41","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-013-0550-8"},{"key":"2026051710001996000_13.1.e001879.42","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13075-022-02871-1","article-title":"Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study","volume":"24","author":"Jeong","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"2026051710001996000_13.1.e001879.43","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/21645515.2018.1514228","article-title":"Herpes zoster vaccination in systemic lupus erythematosus: the current status","volume":"15","author":"Mok","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"2026051710001996000_13.1.e001879.44","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209973"},{"key":"2026051710001996000_13.1.e001879.45","first-page":"566","article-title":"Hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologics treatment","volume":"215","author":"Chen","year":"2017","journal-title":"J Infect Dis"},{"key":"2026051710001996000_13.1.e001879.46","doi-asserted-by":"crossref","first-page":"770124","DOI":"10.3389\/fmed.2021.770124","article-title":"Hepatitis B Virus Reactivation Associated With Therapeutic Interventions","volume":"8","author":"Chang","year":"2022","journal-title":"Front Med"},{"key":"2026051710001996000_13.1.e001879.47","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13504"},{"key":"2026051710001996000_13.1.e001879.48","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2188\/jea.JE20190055","article-title":"Meta-regression Analysis of Sex- and Birth Year-Specific Prevalence of HBsAg and Anti-HCV Among Un-diagnosed Japanese: Data From the First-time Blood Donors, Periodical Health Checkup, and the Comprehensive Health Checkup With Lifestyle Education (Ningen Dock)","volume":"30","author":"Akita","year":"2020","journal-title":"J Epidemiol"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2025-001879","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T17:00:30Z","timestamp":1779037230000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2025-001879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,5,17]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/lupus-2025-001879"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2025-001879","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}